Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | DHFR | P00374 | 2/20 | 0.60 |
| ▸ | ERN1 | O75460 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 2/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243230 | 1.00 | CA12 (0.62) | CA12CA1CA2CA9DHFR | |
| SCHEMBL2569067 | 0.89 | LOXL2 (0.71) | CA12CA1CA2CA9DHFR | |
| SCHEMBL6481471 | 0.89 | CA12 (0.61) | CA12CA1CA2CA9DHFR | |
| SCHEMBL27715902 | 0.88 | CA12 (0.71) | CA12CA1CA2CA9ERN1 | |
| SCHEMBL259 | 0.88 | CA12 (0.59) | CA12CA1CA2CA9DHFR | |
| SCHEMBL8872555 | 0.88 | CA12 (0.59) | CA12CA1CA2CA9DHFR | |
| SCHEMBL68931 | 0.86 | CA12 (0.69) | CA12CA1CA2CA9ERN1 | |
| SCHEMBL7149403 | 0.86 | CA12 (0.58) | CA12CA1CA2CA9DHFR | |
| SCHEMBL7177442 | 0.86 | NR1H4 (0.60) | CA12CA1CA2CA9DHFR | |
| SCHEMBL67941 | 0.86 | CA12 (0.68) | CA12CA1CA2CA9ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846707-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein | UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | UNIVERSITY OF TORONTO MISSISSAUGA (CA) | 2013-08-29 | — | — | US | disclosed |
| WO-2012018868-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038708-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | CA12 4080/4885CA1 2562/4885CA2 389/4885 |
| US-20130225621-A1 | SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN | STAT3, STAT1, STAT4 | CA12 4080/4885CA1 2562/4885CA2 389/4885 |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | STAT3, STAT1, STAT4 | CA12 4080/4885CA1 2562/4885CA2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.